J&J Closes the Loop with Animas Acquisition

Executive Summary

Johnson & Johnson, whose LifeScan Inc. division is number one in the $6 billion glucose monitoring industry, acquired Animas, which after Medtronic MiniMed, is the number two player in the insulin pump market. J&J gets not only a leading insulin pump business, but also technology that lends itself to the future goals of all diabetes companies; the development of an artificial pancreas, or at least, the ability to automatically deliver insulin in response to automated continuous blood glucose measurements.